OriCAR-017 is under clinical development by Oricell Therapeutics (Shanghai) and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OriCAR-017’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OriCAR-017 overview

OriCAR-017 is under development for the treatment of relapsed and refractory multiple myeloma. The drug candidate comprises of T cells genetically engineered to express chimeric antigen receptor targeting cells expressing G protein-coupled receptor class C group 5 member D (GPRC5D). It is administered by intravenous route.

Oricell Therapeutics (Shanghai) overview

Oricell Therapeutics (Shanghai) (Oricell Therapeutics) is a developer of novel drugs for tumor immunotherapy. Oricell Therapeutics is headquartered in Shanghai, China.

For a complete picture of OriCAR-017’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.